152.48 USD
+1.6 (+1.06%)
152.57 USD
+0.09 (+0.06%)
Taking everything into account, NBIX scores 7 out of 10 in our fundamental rating. NBIX was compared to 534 industry peers in the Biotechnology industry. NBIX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. NBIX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes NBIX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year NBIX was profitable.
NBIX had a positive operating cash flow in the past year.
NBIX had positive earnings in each of the past 5 years.
In the past 5 years NBIX always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of NBIX (10.03%) is better than 94.01% of its industry peers.
Looking at the Return On Equity, with a value of 14.25%, NBIX belongs to the top of the industry, outperforming 94.76% of the companies in the same industry.
NBIX has a Return On Invested Capital of 11.10%. This is amongst the best in the industry. NBIX outperforms 94.76% of its industry peers.
NBIX had an Average Return On Invested Capital over the past 3 years of 11.40%. This is significantly below the industry average of 18.60%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
NBIX's Profit Margin of 15.95% is amongst the best of the industry. NBIX outperforms 93.07% of its industry peers.
In the last couple of years the Profit Margin of NBIX has grown nicely.
NBIX's Operating Margin of 20.64% is amongst the best of the industry. NBIX outperforms 94.94% of its industry peers.
In the last couple of years the Operating Margin of NBIX has declined.
The Gross Margin of NBIX (98.37%) is better than 97.57% of its industry peers.
In the last couple of years the Gross Margin of NBIX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
NBIX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for NBIX has been increased compared to 1 year ago.
The number of shares outstanding for NBIX has been increased compared to 5 years ago.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
NBIX has an Altman-Z score of 8.81. This indicates that NBIX is financially healthy and has little risk of bankruptcy at the moment.
NBIX's Altman-Z score of 8.81 is amongst the best of the industry. NBIX outperforms 81.65% of its industry peers.
NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.81 |
ROIC/WACC1.28
WACC8.69%
2.3 Liquidity
A Current Ratio of 3.38 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Current ratio (3.38) which is comparable to the rest of the industry.
A Quick Ratio of 3.27 indicates that NBIX has no problem at all paying its short term obligations.
NBIX has a Quick ratio (3.27) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
Measured over the past years, NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
Looking at the last year, NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
Based on estimates for the next years, NBIX will show a very strong growth in Earnings Per Share. The EPS will grow by 35.05% on average per year.
NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.42% yearly.
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.42%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 36.48, the valuation of NBIX can be described as expensive.
Based on the Price/Earnings ratio, NBIX is valued cheaper than 91.39% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, NBIX is valued a bit more expensive.
With a Price/Forward Earnings ratio of 22.10, NBIX is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NBIX indicates a rather cheap valuation: NBIX is cheaper than 92.70% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of NBIX to the average of the S&P500 Index (36.22), we can say NBIX is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.48 | ||
| Fwd PE | 22.1 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, NBIX is valued cheaper than 93.63% of the companies in the same industry.
NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. NBIX is cheaper than 93.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.63 | ||
| EV/EBITDA | 22.83 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NBIX may justify a higher PE ratio.
NBIX's earnings are expected to grow with 36.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.68
PEG (5Y)0.62
EPS Next 2Y44.8%
EPS Next 3Y36.99%
5. Dividend
5.1 Amount
NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
152.48
+1.6 (+1.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.77%
Inst Owner Change2.13%
Ins Owners1.01%
Ins Owner Change-0.31%
Market Cap15.20B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target177.35 (16.31%)
Short Float %3.43%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)2.85%
PT rev (3m)4.47%
EPS NQ rev (1m)4.68%
EPS NQ rev (3m)6.87%
EPS NY rev (1m)9.8%
EPS NY rev (3m)11.74%
Revenue NQ rev (1m)2.36%
Revenue NQ rev (3m)2.77%
Revenue NY rev (1m)2.21%
Revenue NY rev (3m)2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 36.48 | ||
| Fwd PE | 22.1 | ||
| P/S | 5.67 | ||
| P/FCF | 25.63 | ||
| P/OCF | 23.88 | ||
| P/B | 5.06 | ||
| P/tB | 5.12 | ||
| EV/EBITDA | 22.83 |
EPS(TTM)4.18
EY2.74%
EPS(NY)6.9
Fwd EY4.52%
FCF(TTM)5.95
FCFY3.9%
OCF(TTM)6.39
OCFY4.19%
SpS26.91
BVpS30.12
TBVpS29.77
PEG (NY)0.68
PEG (5Y)0.62
Graham Number53.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.81 |
F-Score5
WACC8.69%
ROIC/WACC1.28
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y53.46%
EPS Next 2Y44.8%
EPS Next 3Y36.99%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.74%
Revenue Next 3Y15.88%
Revenue Next 5Y12.42%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year2.32%
EBIT Next 3Y23.13%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / NBIX FAQ
What is the fundamental rating for NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to NBIX.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
ChartMill assigns a valuation rating of 7 / 10 to NEUROCRINE BIOSCIENCES INC (NBIX). This can be considered as Undervalued.
What is the profitability of NBIX stock?
NEUROCRINE BIOSCIENCES INC (NBIX) has a profitability rating of 8 / 10.
What are the PE and PB ratios of NEUROCRINE BIOSCIENCES INC (NBIX) stock?
The Price/Earnings (PE) ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 36.48 and the Price/Book (PB) ratio is 5.06.